Moving from mandate to mission: Community outreach and engagement at NCI-designated cancer centers “COE is broken.” – The Cancer Letter

Acting Director Dr. Krzysztof Ptak’s words reverberated throughout the meeting room—and the heads of several of us—during the National Cancer Institute’s Office of Cancer Centers update on the final day of the 2024 Association of American Cancer Institutes/Cancer Center Administrators Forum Annual Meeting in Chicago. To access this subscriber-only content please log in or subscribe.If […]

Read the full article here

Source: cancerletter.com

Categories: Oncologists1, General Medicine News

Tweets with this article

The Cancer Letter

Moving from mandate to mission: Community outreach and engagement at NCI-designated cancer centers. Guest editorial by @drmonicabaskin, @DrNJBarrett, Kim F. Rhoads, @HayleyBrooklyn, Kimlin Tam Ashing, @DrOdedina, and @DrVBSheppard. https://t.co/YVGUyXaQ5P

Related Articles

Ponsegromab for the Treatment of Cancer Cachexia | NEJM

Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a…

Ricardo Carvalho December 26, 2024

OCE Scientific Collaborative

OCE Scientific Collaborative

FDA Oncology December 26, 2024

#ASH24: Treatments for R/R AML, maintenance strategies, and mutation- and MRD-informed decisions

Catch up with our live social media coverage of treatments for R/R AML, maintenance therapy, and mutation- and MRD-informed decisions from the 66th ASH Annual…

AML Hub December 26, 2024

Non-T-depleted haploidentical transplantation in patients with secondary AML

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, comments on the value of non-T-depleted haploidentical transplantation in patients with secondary acute myeloid leukemia (AML)…

VJHemOnc December 26, 2024

FAST-Forward: safety of ultra-hypofractionated radiotherapy on cardiac health

Icro Meattini, MD, University of Florence, Florence, Italy, comments on the results of the FAST-Forward trial (ISRCTN19906132), stating that ultra-hypofractionated radiotherapy, as per the trial,…

VJ Oncology December 26, 2024

Combinatorial strategies targeting NEAT1 and AURKA as new potential therapeutic options for multiple myeloma

Multiple myeloma (MM) is a dreadful disease, marked by the uncontrolled proliferation of clonal plasma cells (PCs) within the bone marrow (BM). MM is characterized…

Haematologica December 26, 2024

IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia

IO-202 plus azacitidine elicited an ORR of 66.7% in patients with HMA-naive chronic myelomonocytic leukemia.

OncLive.com December 26, 2024

Navtemadlin Reduces Spleen Size and Symptom Score in R/R Myelofibrosis

Navtemadlin monotherapy was safe and effective among patients with myelofibrosis who were relapsed or refractory to treatment with JAK inhibitors.

OncLive.com December 26, 2024

Dexamethasone-Sparing Regimen Improves Outcomes in Frail MM Patients

Daratumumab and lenalidomide improved survival outcomes over lenalidomide and dexamethasone in frail patients with newly diagnosed MM.

CancerTherapyAdvisor December 26, 2024

Call-for-Papers | JACC: CardioOncology

Submission Deadline: February 15, 2025 Cardio-oncology historically has focused on the cardiotoxic effects of cancer therapies; however, as our field continues to evolve, there is…

Oncology Advance December 26, 2024